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Mitral Regurgitation Augments
Post-Myocardial Infarction Remodeling
Failure of Hypertrophic Compensation
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Boston, Massachusetts; Jerusalem, Israel; and Charleston, South Carolina
Objectives We examined whether mitral regurgitation (MR) augments post-myocardial infarction (MI) remodeling.
Background MR doubles mortality after MI, but its additive contribution to left ventricular (LV) remodeling is debated and has
not been addressed in a controlled fashion.
Methods Apical MIs were created in 12 sheep, and 6 had an LV-to-left atrial shunt implanted, consistently producing re-
gurgitant fractions of 30%. The groups were compared at baseline, 1, and 3 months.
Results Left ventricular end-systolic volume progressively increased by 190% with MR versus 90% without MR (p 
0.02). Pre-load–recruitable stroke work declined by 82  13% versus 25  16% (p  0.01) with MR, with de-
creased remote-zone sarcoplasmic reticulum Ca2-ATPase levels (0.56  0.03 vs. 0.76  0.02, p  0.001), and
decreased isolated myocyte contractility. In remote zones, pro-hypertrophic Akt and gp130 were upregulated in
both groups at 1 month, but significantly lower and below baseline in the MR group at 3 months. Pro-apoptotic
caspase 3 remained high in both groups. Matrix metalloproteinase (MMP)-13 and membrane-type MMP-1 were
increased in remote zones of MR versus infarct-only animals at 1 month, then fell below baseline. The MMP
tissue inhibitors rose from baseline to 3 months in all animals, rising higher in the MI  MR–group border
zone.
Conclusions In this controlled model, moderate MR worsens post-MI remodeling, with reduced contractility. Pro-hypertrophic
pathways are initially upregulated but subsequently fall below infarct-only levels and baseline; with sustained
caspase 3 elevation, transformation to a failure phenotype occurs. Extracellular matrix turnover increases in MR
animals. Therefore, MR can precipitate an earlier onset of dilated heart failure. (J Am Coll Cardiol 2008;51:
476–86) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.07.093c
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cxpansion of infarcted tissue begins acutely after myocardial
nfarction (MI). A more gradual remodeling process, how-
ver, also involves the noninfarcted areas (1,2); initially
ompensatory, this process subsequently becomes mal-
daptive, generating a larger, more spherical, and poorly
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ccepted July 16, 2007.ontracting ventricle (3–7), associated with reduced sur-
ival (2,8,9).
See page 487
Myocardial infarction can also cause mitral regurgitation
MR) by altering ventricular geometry and function (10–
2). Such ischemic MR doubles the risk of death after MI
13,14). Severe nonischemic MR has been shown to pro-
ote left ventricular (LV) remodeling and reduce survival
15–19). However, whether more typically moderate isch-
mic MR does so remains controversial. A recent paper
aintained that “ischemic MR is a consequence, not a
ause, of post-infarction remodeling,” because remodeling
ersisted despite annuloplasty with apparent MR reduction
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January 29, 2008:476–86 MR Augments Post-MI Remodeling20). Practically, “MR might not represent a target for
herapy if indeed it is not the major culprit” (21), adding to
he uncertainty regarding the risk versus benefit of repairing
schemic MR (22).
In patients, ischemic myocardial changes and regurgita-
ion develop concurrently, precluding the ability to separate
heir effects and analyze their interaction directly (23). This
equires a model in which MR can be varied independently
n the presence of MI, but without interventions such as
nfarct patching (24–27) that might themselves influence
emodeling. Most experimental studies of post-MI remod-
ling have used an infero-posterior MI model (27,28); this
as the disadvantage of linking the MI-induced remodeling
o the development of MR. We therefore tested the
ncremental contribution of MR in a controlled manner
sing a model in which the MI by itself does not cause MR,
nd the MR can be created in a standardized and fixed
ashion (29,30).
In such a study, it must be recalled that remodeling is a
omplex process, involving changes not only in ventricular
eometry (3) and in global and regional myocardial function
31), but also in calcium handling, molecular signals pro-
oting hypertrophy, cardiomyocyte viability (32–34), and
xtracellular matrix turnover (35). Intracellular pathways
hat promote compensatory hypertrophy also tend, if chron-
cally activated, to drive cells down pathways to cell death by
poptosis and thus to loss of contractile elements, with
urther deterioration of cardiac function (Fig. 1). Accord-
ngly, it is important to correlate evidence of remodeling at
he molecular, cellular, and whole-heart levels (36). We
herefore tested the hypothesis that MR accompanying MI
roduces greater remodeling than a comparable infarct
lone, and may be associated with a different progression of
olecular events, with transition from signals promoting
ypertrophy to those inducing failure.
Figure 1 The Vicious Cycle of Remodeling
EC  extracellular; LV  left ventricle; MR  mitral regurgitation.oethods
R model. A modification of
he chronic MR sheep model of
ankin et al. (29) was imple-
ented in conjunction with Luis
uerrero, a surgeon experienced
n physiological modeling, using
n 8-cm long, 8-mm diameter
einforced Teflon (PTFE) graft
Edwards Lifesciences, Irvine,
alifornia) (cross-sectional area
f 0.50 cm2) implanted under
terile conditions into the LV
ase and left atrial (LA) append-
ge with intramuscular portions
tiffened with epoxy resin (Fig.
). The regurgitant flow was
onfirmed during each thoracot-
my (see the following text) us-
ng a transonic flow probe and
olor Doppler echocardiography imaging. The standardized
hunt diameter and length have produced consistent levels
f MR (regurgitant fractions of approximately 30%, corre-
ponding to moderate MR [37]). Animals were treated with
eparin (3 days) and then oral aspirin.
nimal studies. A total of 12 Dorsett hybrid sheep (20 to
0 kg) were loaded for 3 days with amiodarone (200 mg
rally twice a day) then anesthetized with thiopentothal
odium (0.5 ml/kg), intubated, and ventilated at 15 ml/kg
ith a 2% isoflurane-oxygen mixture. All received glyco-
yrrolate (0.4 mg intravenously) and prophylactic vancomy-
in (0.5 g intravenously) and amiodarone (150 mg intrave-
ous drip over the course of the operation). Surface
lectrocardiogram (ECG) was monitored, and a sterile left
horacotomy performed with pericardial incision and cre-
tion of a cradle. A high-fidelity micromanometer-tipped
atheter (Millar Instruments Inc., Houston, Texas) was
laced into the LV. After baseline 2-dimensional (2D) and
-dimensional (3D) echocardiography imaging, an antero-
pical MI was produced by ligating the mid- to distal left
nterior descending coronary artery, known to produce a
ubstantial MI without MR (38). An immediate 2D echo-
ardiography apical image was performed to confirm that
eptal wall motion abnormality extended approximately
ne-third of the way from LV apex to base for standard-
zation. Mitral regurgitation equivalent volume overload
as created for 90 days in 6 sheep with an open LV-to-LA
hunt (referred to as the infarct  MR group); in the other
, the shunt was closed (infarct-only group). In addition to
nalgesia, propranolol, 1 mg intravenously in 2 divided
oses, was given for evident stress and sinus tachycardia
150) upon extubation. Antibiotics (cephapirin, 0.5 g
ntravenously) and analgesics (buprenorphine, 0.3 mg
wice a day) were administered for the next 5 days, and
Abbreviations
and Acronyms
EF  ejection fraction
LA  left atrium/atrial
LV  left
ventricle/ventricular
MI  myocardial infarction
MMP  matrix
metalloproteinase
MR  mitral regurgitation
MT-MMP  membrane-type
matrix metalloproteinase
SERCA2a  sarcoplasmic
reticulum Ca2-ATPase
TIMP  tissue inhibitor of
matrix metalloproteinase
2D  2-dimensional
3D  3-dimensionalral amiodarone (200 mg twice a day) for the next 3.
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MR Augments Post-MI Remodeling January 29, 2008:476–86During repeat sterile thoracotomy at day 30, 3D echo-
ardiography was performed to evaluate LV remodeling and
unction, with directed biopsies of the noninfarcted myo-
ardium near and remote from the border zone using a
ruCut needle (Cook, Winston-Salem, North Carolina).
t day 90, 3D echocardiography and blood sampling were
epeated at thoracotomy, followed by euthanasia and whole-
eart pathological and myocyte size and contractility studies
hat require considerable tissue. The animal studies con-
ormed to National Institutes of Health Guidelines for
nimal Research (Guide for the Care and Use of Labora-
ory Animals, National Research Council, Washington,
C, 1996) and were approved by the institutional animal
are committee.
D echocardiography and LV function. Three-
imensional quantitation is necessary because LV shape
hanges with chronic MR, as well as MI (39). Rotated
pical images were obtained at 10° intervals with an epicar-
ial 5-MHz transesophageal echocardiography probe (So-
os 7500, Philips Medical Systems, Andover, Massachu-
etts), rotated by software and gated to ECG and
espiration. Digital images were analyzed on a workstation
ith custom programs (40). Endocardial surfaces were
raced to calculate LV volumes and ejection fraction (EF),
nd coded for wall motion abnormality to produce a
uantitative 3D wall motion map validated against a 36-
rystal sonomicrometer array (41). Remodeling was quan-
ified in terms of increasing LV volumes (42). Regurgitant
raction was calculated as transonic MR-equivalent flow
ivided by LV ejection volume, with cross-correlation by
ulsed Doppler time–velocity integral of shunt flow multi-
lied by shunt cross-sectional area. At thoracotomy, the
nitial and final pressure–volume loops were obtained using
illar catheters and 4 sterile subendocardial crystals (Sono-
etrics Corp., London, Ontario, Canada), with an inferior
ena cava occlusion to obtain the end-systolic pressure–
olume relation for contractility (43) and pre-load–
ecruitable stroke work (44). Crystals were located at the LV
pex and base (between aorta and mitral annulus) and
Figure 2 Schematic and 2D Echocardiographic
Image of the LA-LV Shunt Creating MR
Single arrows indicate flow direction; paired arrows indicate shunt exit from
the LV. LA  left atrial; MI  myocardial infarction; 2D  2-dimensional; other
abbreviations as in Figure 1.nteriorly and posteriorly along a midventricular short-axis. srystals were not placed at day 30 to maximize sterility and
urvival. dP/dt was obtained by the high-fidelity Millar
atheter (Millar Instruments, Houston, Texas).
yocyte size and contraction. Small (5 to 10 g) areas of
issue were removed at euthanasia from the noninfarcted
V and perfused via the corresponding coronary artery for 5
in with low-magnesium Krebs-Henseleit (KH) cardiople-
ia solution. Myocardial cells were isolated using a well-
stablished method (45,46). The LV sections were perfused
ith Ca2-free KH containing collagenase (Worthington
iochem Corp., Lakewood, New Jersey) and hyaluronidase
Sigma, St. Louis, Missouri). Ventricular muscle tissue was
inced into small pieces and placed in enzyme buffer I
Sigma) in the presence of trypsin and deoxy-ribonuclease.
he tissue was washed in a 3:1 mixture of Ca2-free KH in
ulbecco’s phosphate-buffered saline (GIBCO, Gaithers-
urg, Maryland). Cells were loaded with the Ca2 fluores-
ent indicator Fura-2 for 15 min in a light-sealed chamber
ounted on an inverted microscope. Myocyte length and
idth were measured offline on 50 consecutive cells using
ommercial image analysis software to establish proportions
f normal short cells versus elongated cells characteristic of
ccentric hypertrophy in the failing phenotype. The cells
ere excited to contract using platinum electrodes in the
ath, and a dual excitation spectrofluorometer recorded
uorescence emissions (505 nm from exciting wavelengths
40 mm and 380 mm) to calculate intracellular calcium
oncentrations. Cell motion was measured by a video-edge
otion detector (Crescent Electronics, Sandy, Utah) (45).
olecular assays. We measured levels of several molecular
pecies that determine cell contractility, that modulate cell
ypertrophy and death, and that are responsible for extra-
ellular matrix turnover. All protein assays were performed
nd specimens pooled from the same treatment group and
tage.
alcium cycling proteins: sarcoplasmic reticulum Ca2-
TPase (SERCA2a) and phospholamban. Sarcoplasmic
eticulum membranes were obtained from the myocardial
iopsy specimens using a sucrose gradient centrifugation
ethod (47). Myocardium was homogenized and centri-
uged at 7,700 g for 20 min, and the supernatant filtered and
entrifuged at 136,000 g for 60 min. The pellets, resus-
ended and rehomogenized in 10% sucrose buffer, were
entrifuged at 55,000 g in a 10% to 40% sucrose gradient,
nd the bands between 30% and 40% enriched in sarcoplas-
ic reticulum were collected, centrifuged at 136,000 g for
0 min, and the pellet resuspended in freezing buffer.
rotein was determined by a modified Bradford procedure
using bovine serum albumin for the standard curve).
roteins were separated from the sarcoplasmic reticulum
esicle preparation from tissue frozen in liquid nitrogen, and
n immunoblot using monoclonal anti-SERCA2 and phos-
holamban performed. Proteins levels were normalized
gainst total myocardial protein.
ro-hypertrophic and anti-apoptotic cascades. We mea-ured levels of Akt (protein kinase B) and gp130, which are
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January 29, 2008:476–86 MR Augments Post-MI Remodelingoth at their respective levels (cytosol and membrane)
mportant crossroads in pro-hypertrophic signaling; and
aspase 3, the final common pathway for intracellular
ignaling of apoptosis. Western blot analysis was performed
n cell lysates from biopsies at baseline and days 30 and 90.
ntibodies binding for anti-gp130, anti-phospho Akt, and
ntiactivated caspase 3 (48) were detected with a
eroxidase-conjugated antimouse IgG and chemilumines-
ence. -Actin was used as a housekeeping control. Densi-
ometry of the blots was assessed using commercially avail-
ble software (Photoshop 5, Adobe Systems Inc., San Jose,
alifornia).
odulators of extracellular matrix turnover: matrix met-
lloproteinases (MMPs). Assays were performed for
embrane-type matrix metalloproteinase-1 (MT1-MMP),
MP-13, tissue inhibitor of matrix metalloproteinase
TIMP)-1, and TIMP-4 by immunoblotting using methods
reviously described (35). Left ventricular myocardial sam-
les were homogenized and concentrated to prevent MMP
roteolytic activation and degradation. Trypsin (2.5 M; 5
in) was used to cleave nascent MMPs to fully activate
nzyme moieties and/or facilitate the removal of endoge-
ous inhibitors. Relative TIMP-1, TIMP-4, MT1-MMP,
nd MMP-13 levels were then measured by immunoblot-
ing. A positive control was included in all immunoblots
MMP-13: CC068; MT1-MMP: CC1042) (Chemicon,
emecula, California).
tatistics. Statistical analysis was performed using a Stu-
ent t test for continuous variables and a chi-square test for
ategorical variables (Stat View 5, SAS Institute Inc., Cary,
orth Carolina). A value of p  0.05 was considered
ignificant. Multiple comparisons were performed using
nalysis of variance (for repeated measurement where
eeded) and a Student-Neumann Keuls post-hoc test.
nterobserver and intraobserver variability for 3D echo-
easured LV volumes and EF in our laboratory is 3.5%.
esults
emodeling: LV volumes. Left ventricular end-diastolic
olume relative to the acute post-MI value increased by an
verage of 26% in the infarct-only group versus 130% in
hose with volume overload (p  0.02). Left ventricular
nd-systolic volume progressively increased by 190% with
R-type volume overload versus 90% with MI only (p 
.02) (Figs. 3 and 4).
emodeling: LV function. Pre-load–recruitable stroke
ork from pressure-volume loops declined more in the
nfarct  MR group by 82  13% versus 25  16% of
aseline in the infarct-only group (p  0.01). Left ventric-
lar dP/dt also declined progressively in the MR group to 52
9% of baseline, but only by 22  12% in the shams (p 
.04) (Fig. 4). These results were corroborated by reduced
ontractility of isolated cells with reduced calcium transients
nd increased diastolic intracellular calcium concentration
Tables 1 and 2). The diastolic relaxation constant tau was sore prolonged in the infarctMR group (78 23 ms vs.
4  13 ms, p  0.01).
alcium cycling proteins. As shown in Figure 5,
ERCA2a abundance was downregulated in the infarct
egion and border zone compared with the remote region in
oth infarct  MR and infarct-only sheep LVs. There was
lower level of SERCA2a in the remote zone of infarct 
R than of infarct-only sheep. Phospholamban was un-
hanged in all regions. These changes are typical for
emodeling myocardium.
ntracellular signaling pathways. Akt, a pro-hypertrophic
nzyme (49), was upregulated in the remote zones of infarct
MR and infarct-only animals at 1 month, but was lower
n animals with than without MR at 3 months (Fig. 6). In
he infarct  MR group at 3 months, Akt also fell below
aseline of the same group. The same pattern was observed
or the interleukin-6-family receptor subunit gp130 (50).
xpression of activated caspase 3 (32–34,51), the final
ommon pathway of apoptosis, remained elevated in all
egions of both groups at both 1 and 3 months.
ell morphology. Myocytes in the MR group were elon-
ated, characteristic of myocardial failure (45), compared
ith cells from the MI-only animals (Fig. 7).
xtracellular matrix and MMPs. In the remote myocar-
ium of infarct MR sheep, at initial follow-up, there was
significant increase in MMP-13 and MT1-MMP, fol-
owed by a decrease at the time of sacrifice (Fig. 8, “shunt
emote” bars): MMP-13 increased to 238 29% of baseline
t follow-up, and then fell to 79  13% of baseline at 3
onths sacrifice; MT1-MMP increased to 165  23% of
aseline at follow-up, and then fell to 85  16% of baseline
t sacrifice. In the remote myocardium of infarct-only
Figure 3 Echocardiographic 3D Reconstructions
of the Endocardial Surface of the LV
Echocardiographic 3-dimensional (3D) reconstructions of the endocardial sur-
face of infarct (MI) only (A and B) and infarct  MR (C and D) animals at dias-
tole (top) and systole (bottom). Note the enlarged and spherical infarct  MR
ventricles. Abbreviations as in Figures 1 and 2.heep, the rise and fall of MMP-13 did not reach statistical
s
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MR Augments Post-MI Remodeling January 29, 2008:476–86ignificance (170  85% of baseline at initial follow-up; 75
22% at sacrifice), and MT1-MMP did not significantly
Figure 4 Measurement of LV Volumes and Function
End-diastolic volume (EDV) (A) and end-systolic volume (ESV) (B) of infarct-only
(yellow bars) and infarct  MR (red bars) sheep at baseline (pre), 1 month
follow-up (f/u), and 3 months sacrifice. (C and D) dP/dt and pre-load–recruit-
able stroke work (PRSW) of infarct-only (broken lines) and infarct  MR (solid
lines) sheep at pre, f/u, and 3 months sacrifice. *p  0.05. Abbreviations as
in Figure 1.ncrease at 1 month (Fig. 8, “sham remote” bars). In the
rorder zones of the infarct-only sheep, there was a signifi-
ant decrease in MT1-MMP at sacrifice (to 60  8% of
aseline), with levels maintained in the infarct  MR
roup. In contrast, TIMP-4 showed progressive rises from
aseline to initial follow-up and then to sacrifice in the
order and remote zones of both groups, with significantly
igher levels at sacrifice in the infarct  MR group border
one (207  9% vs. 152  10% of baseline, p  0.05).
issue inhibitor of matrix metalloproteinase-1 showed a
imilar pattern of progressive increases in the infarct MR
roup remote zone, with a significant late rise at sacrifice.
iscussion
yocardial infarction, with loss of contracting myocytes,
eads to a sequence of events aimed at preserving cardiac
utput, including increased LV end-diastolic volume to
ugment pre-load. Cells in noninfarcted areas hypertrophy
y addition of contractile elements in series, creating eccen-
ric hypertrophy without increased wall thickness. This
llows the LV to dilate, a process that is also promoted by
ltered MMP activation with extracellular matrix degrada-
ion (52), and acceleration of cell death by apoptosis (32,53).
his process eventually culminates in systolic enlargement,
xtensive fibrosis, and LV failure, the extent of which
redicts further cardiac events (2,9). Volume and pressure
verload increase wall stress, which can aggravate remodel-
ng (54) and promote eccentric hypertrophy through in-
reased fiber stretch (Fig. 1). Conversely, hemodynamically
nloading the LV reverses the functional and cellular
tigmata of cardiac failure as well as the remodeling process
55,56). Neurohumoral activation and activation of inflam-
atory mediators and cytokines initially compensate for
educed cardiac output but, in the long term, mediate
ncreased load, cell death, and cardiac fibrosis (50,57–59).
ncreased wall stress also up-regulates the production and
solated Cardiomyocytentractility in the Different Groups
Table 1 Isolated CardiomyocyteContractility in the Different Groups
Contractility
Measurements
Normal
Control Sheep Infarct  MR Infarct Only
Cell shortening (%) 5.7 0.4 2.6 0.7* 3.5 0.3*†
t90% (ms) 390 82 676 68* 510 59*†
p  0.01 compared with normal control sheep; †p  0.01 compared with infarct  mitral
egurgitation (MR) group.
t90%  time to 90% relaxation.
ntracellular Calciume surements in the Different Groups
Table 2 Intracellular CalciumMeasurements in the Different Groups
Calcium
Measurements
Normal
Control Sheep Infarct  MR Infarct Only
Diastolic (Ca2) (nM) 230 41 320 21* 275 22*†
Systolic (Ca2) (nM) 796 24 535 44* 714 43*‡
t90% (ms) 361 34 542 38* 455 43*†
p  0.01 compared with normal control sheep; †p  0.03 compared with infarct  mitral
egurgitation (MR) group; ‡p  0.005 compared with infarct  MR group.
t90%  time to 90% relaxation of the calcium signal.
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January 29, 2008:476–86 MR Augments Post-MI Remodelingelease of MMPs, which are believed to be pivotal in
ltering the extracellular matrix in ways that promote
entricular dilatation (60). Their transgenic activation in-
uces congestive heart failure (61), and their inhibition
ttenuates post-MI remodeling (62,63).
Mitral regurgitation, caused by alterations in ventricular
eometry and function after MI (10,12), can itself initiate
he remodeling cascade, and causes progressive deterioration
f ventricular function at a cellular and molecular level
15–17). Mitral regurgitation considerably alters the load on
he LV. It increases diastolic wall stress, which can induce
ccentric LV hypertrophy and subsequent dilatation and
ailure (18), and it thereby increases early systolic wall stress.
lthough MR permits LV emptying during systole into the
ower-pressure LA, it has been shown actually to increase
nd-systolic wall stress and, hence, afterload in patients with
hronic MR (64,65). Moreover, MR induces further LV
ilatation due to activation of neurohumoral and cytokine
omponents of the remodeling cascade (66–68). As MR is
oth a cause and a result of LV remodeling, it can
otentially exacerbate the vicious cycle spiraling down to
ardiac failure unless the remodeling or the MR is reversed
69–71).
Regarding clinical implications, knowing whether the
arallel occurrence of MR and MI causes more pronounced
emodeling is critical, because at least MR can be eliminated
y repairing or replacing the valve, and thus relieving the
olume overload induced by it. Separating these 2 dynamic
Figure 5 SERCA2a and Phospholamban Quantification
(A) Quantification of sarcoplasmic reticulum Ca2-ATPase (SERCA2a) activity in re
Immunoblots from different regions of the myocardium in different groups for SERC
dium that was homogenized and protein extracted. Abbreviations as in Figures 1 arocesses in an experimental model is a challenge, because on most existing models they are linked. One recent study of
nferior MIs, in fact, concluded that prevention of ischemic
R does not influence the outcome of remodeling (20),
espite benefits in nonischemic models (18) and concerns in
onischemic patients (72). In our model, we therefore
mplanted an LV-to-LA shunt, which created a moderate
nd standardized MR-like regurgitant flow, independent of
medium-sized antero-apical MI that by itself does not
ause MR.
In this controlled model, moderate MR worsened
ost-MI remodeling. Specifically, it induced large diastolic
nd systolic LV volumes reflecting volume overload and
educed global function. Reduced contractility was also
pparent in less pre-load–dependent physiological measures
uch as pre-load–recruitable stroke work. These changes
aralleled decreased single-cell contractility in the nonin-
arcted myocardium with reduced SERCA2a levels, which
irectly correlate with cell contraction (46).
In contrast to progressive changes in the LV, several
ediators of the hypertrophic process underwent biphasic
hanges in the noninfarcted myocardium of animals with
R-type volume overload. These include gp130, a glyco-
rotein that forms heterodimers to produce different recep-
ors, notably of the interleukin 6/CT1/LIF family. The
ctivation of these receptors has been linked to cardiomyo-
yte hypertrophy (50,73), and their reduced abundance,
anifested by reduced gp130 levels, has been associated
ith the transition from hypertrophy to failure (74,75). Akt,
border, and infarct regions of experimental and normal control sheep hearts. (B)
nd phospholamban. Note that in the infarct region, there was residual myocar-mote,
A2a a
nd 2.r protein kinase B, is a serine-threonine kinase activated by
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MR Augments Post-MI Remodeling January 29, 2008:476–86everal pro-survival and -hypertrophic factors, among others
ardiotrophin-1 (76), acting through the gp130-containing
eceptor, or growth factor receptors activating
hosphoinositide-3 kinase (77).The constitutive activation
f Akt in a model of rat ischemia-reperfusion injury reduced
ell death and improved function (78). Like gp130, reduced
evels of Akt are related to increased apoptosis and a
ransition from compensatory hypertrophy to a failure
henotype (49). In our model, while both infarctMR and
nfarct-only sheep had elevated expression of Akt and gp130
fter 1 month, the MR sheep demonstrated a notable
eduction in these protein levels after 3 months, compared
ith the no-MR animals and with baseline. The pro-
ypertrophic process, which begins in both groups at 1
onth, continues in the animals without MR but is down-
egulated at 3 months in the MR group, in association with
ontinued adverse remodeling and LV dysfunction. This
ecline may represent earlier termination of the hypertro-
Figure 6 Protein Levels of Akt, gp130, and Caspase 3
Protein expression of Akt, gp130, and activated caspase 3 from infarct-only
(broken lines) and infarct  mitral regurgitation (solid lines) sheep at base-
line, 1 month follow-up (f/u), and 3 months sacrifice. Note the biphasic change
in infarct  mitral regurgitation animals for gp130 and Akt expression at fol-
low-up (high) and sacrifice, while no significant change is noted in caspase 3
levels. Values are  standard error of the mean, *p  0.01.hic process or transition to a failure phenotype specific tohe persistent-MR situation; either way, it represents failure
f the hypertrophic process. The ongoing drive to cell death,
ith the suppressed pro-hypertrophic drive, further pro-
otes the transition to failure. These findings are consistent
ith the emerging view of LV remodeling in general as a
ailed attempt at compensation for initial stresses on the
yocardium—in this case, exacerbated by the MR volume
verload (7,74); in others, it reflects the transition from
ypertensive hypertrophy to failure (79,80).
There was also excessive activation of MMPs, notably
MP-13 and MT-MMP1, in the noninfarcted remote
one of the MR sheep. This could induce excess extracel-
ular matrix turnover and potentially exacerbate remodeling.
owever, these same MMP levels fell at sacrifice, with the
all in remote-zone MT-MMP1 being significantly greater
n the MR sheep, and the fall in MMP-13 being significant
nly for the MR group. As this change parallels the
own-regulation of the pro-hypertrophic signaling process,
t could be also part of the failure of compensation by
imiting the adaptive geometrical changes in myocardial
ypertrophy. Matrix metalloproteinase inhibitors showed a
ifferent pattern, with a progressive rise from baseline to
acrifice that was significantly greater with MR. This
uggests a possible shift from matrix turnover to matrix
ccumulation and stabilization over time, a response typical
f remodeling myocardium (81). However, it is clear that
either the MMP nor the TIMP changes adequately
ompensate for the remodeling process, as LV volume
rogressively rose while systolic function fell.
This study has several limitations. Ischemic MR affecting
native valve often progressively increases (28,69–71), but
s inherently linked to the underlying MI and is not
tandardized. Based on the motivation for this study, it was
Figure 7 Photomicrographs of Separated Cardiomyocytes
Elongated myocytes from sheep with MI and MR shunt (A) versus more normal
cells from MI-only animals (B). Note the different scales used to accommodate
the elongated cells of the MI  MR sheep within the field. Abbreviations as in
Figures 1 and 2.
c
g
d
p
t
o
t
c
i
M
r
a
i
p
r
t
t
r
h
p
r
g
a
483JACC Vol. 51, No. 4, 2008 Beeri et al.
January 29, 2008:476–86 MR Augments Post-MI Remodelingritical to separate the 2 processes of infarction and regur-
itation to determine the incremental role of MR most
irectly, and to do so with a standardized orifice, which
rovided stable regurgitant fractions of 30% throughout
he study. Although the LV also fills through this valveless
rifice, based on prior experience, this should not impor-
antly alter LV filling (29).
We did not assess whether any one of the molecular
hanges reported in the present study is causative. We
ntended to test whether differences in remodeling based on
R are associated with molecular changes described in the
emodeling process. Determining which factors are caus-
Figure 8 MMP Abundance
Levels of membrane-type (MT) matrix metalloproteinase (MMP)1 and tissue inhibit
infarct  mitral regurgitation (red bars) animals at first follow-up (T2) and sacrifice
 mitral regurgitation relative to myocardial infarction only animals for the same ztive versus concomitants, and studying all possible factors, cs beyond the scope of this study. Nevertheless, we analyzed
athways extensively linked to the pro-hypertrophic and
emodeling processes, and causally implicated through
ransgenic and pharmacologic modification (61,74,78).
While the impact of isolated MR is important to explore,
he study specifically addresses the challenge posed by the
ecent literature (20), which can be stated as an alternative
ypothesis that remodeling in ischemic MR is caused only or
redominantly by the underlying infarct, not the MR. This
equired comparing infarct-only versus infarct  MR
roups. The data do show important effects of the infarct
lone, with end-systolic volume nearly doubling, and in-
atrix metalloproteinase (TIMP)-4 in the infarct-only (“sham”, green bars) and
ime points. *p  0.05 relative to baseline; #p  0.05 for myocardial infarction
d stage; $p  0.05 for sacrifice relative to initial follow-up.or of m
(T3) t
one anreases in gp130, Akt, and caspase. The changes with infarct
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MR Augments Post-MI Remodeling January 29, 2008:476–86lus MR, however, were greater, with end-systolic volume
early tripling, and a different pattern of activation followed
y exhaustion of hypertrophic- and apoptotic-signaling
olecules gp130 and Akt. The findings, therefore, suggest
n additive rather than exclusive role of MR. This is sup-
orted by our data (unpublished results) from sheep with an
dentical shunt and no MI, which did not cause significant
emodeling in the same 3-month time-frame in terms of
ither volume or contractility changes.
Recently, contribution of MR to post-MI remodeling has
een challenged by Guy et al. (20) in an inferior MI model
n which either MR was reduced using an undersized
nnuloplasty ring repair, or MI was restrained using a mesh.
he MR repair group remodeled more, leading to the
uggestion that the MR is not causative, but may be a
onsequence of post-MI remodeling. The main caveat to
hese conclusions is that undersized ring annuloplasty may
y itself alter LV mechanics, as recently shown (82), so as to
xacerbate remodeling. Thus, the excess remodeling ob-
erved may have been caused, at least partially, by the repair
tself, which was performed 2 weeks before infarct creation.
he difficulty in eliminating MR as a potential contributor
o continued remodeling by annuloplasty has also been
eported (72). Another recent paper (83) has suggested that
epairing MR in a subgroup of patients with LV dysfunc-
ion has no survival benefit. While this is intriguing, the
atient population in that study had prominent LV dys-
unction at baseline (30% EF), and thus it is possible that
epair was performed too late for many to benefit in terms
f LV function or outcome. Based on their inclusion
riteria, the patients also had at least moderate-to-severe
R—more severe than in our model. Further, unlike this
I model, roughly 40% of the patients did not have
oronary artery disease as the basis for their LV dysfunction.
hus, these clinical data cannot readily be compared with
ur relatively mild MI model with normal baseline LV
unction and moderate MR. There is definitely a need for a
andomized controlled study to clinically address the issue
f mitral valve repair in moderate ischemic MR.
onclusions
his study demonstrates that MR accompanying MI pro-
uces greater ventricular remodeling than a comparable
nfarction alone, with an earlier transition to a failure
henotype. This is the case even for only moderate MR,
ost typical of the ischemic situation, for which the greatest
ncertainty exists regarding impact on the heart and need
or intervention. The changes at the level of the whole heart
arallel cellular and molecular abnormalities in the nonin-
arcted myocardium that reflect the complex remodeling
rocess. These molecular events also progress differently
ith MR than with comparable infarction alone, with an
nitial rise in pro-hypertrophic and antiapoptotic signals,
ollowed by their exhaustion. Recognizing this pattern can
otivate a search for the responsible molecular “switch,” so
1hat decompensation might be limited or reversed, averting
he earlier onset of dilated heart failure precipitated by MR
hat may portend a worse prognosis.
eprint requests and correspondence: Dr. Robert A. Levine,
ardiac Ultrasound Laboratory YAW5, Massachusetts General
ospital, 55 Fruit Street, Boston, Massachusetts 02114. E-mail:
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